medigraphic.com
Órgano Oficial de la Sociedad Mexicana de Angiología y Cirugía Vascular

2017, Number 3

<< Back Next >>

Rev Mex Angiol 2017; 45 (3)

Trombosis venosa profunda recurrente: Una entidad anunciada. Experiencia en el Hospital Regional “Lic. Adolfo López Mateos” del ISSSTE

Lozano-Corona R, Flores-Escartín MH, Torres-Martínez JA, Serrano-Lozano JA, Loera-Barragán A, Romero-Espinosa L

Language: Spanish
References: 50
Page: 127-138
PDF size: 145.54 Kb.


ABSTRACT

Aim. To identify the main causes of DVT and its association with the causes and major complications in recurrent DVT in a period of 4 years in the Service of Angiology and Vascular Surgery of the Hospital Regional “Lic. Adolfo López Mateos”.
Background. Deep vein thrombosis has a high rate of recurrence, and factors associated with different treatment regimens that vascular surgeons should know to avoid future thrombotic events.
Material and methods. A retrospective, descriptive and observational study of patients who came to our service for a recurrent venous thrombosis of the lower limbs in the period January 2012 to December 2015 was performed.
Results. 23.8% of recurrences was found of the total cases handled by TVP in that period of time, 38% of them were identified like Idiopathic form, for the first event and 66% for the subsequent. In 100% of recurrences post-thrombotic syndrome occurred, mild in 22% of patients, moderate in 33% and severe in up to 44%.
Conclusions. Recurrent deep vein thrombosis is a frequent condition in our environment associated with many factors, sometimes unknown, and it must be taken into account for the impact that represents in patients.


REFERENCES

  1. Kahn SR, Solymoss S, Lamping, Abenhaim L. Longterm outcomes after deep vein thrombosis: postphlebitic syndrome and quality of Life. J Gen Intern Med 2000; 15: 425-9.

  2. Goldhaber SZ. Prevention of recurrent idiopathic venous thromboembolism. Circulation 2004; 110[suppl IV]: IV-20 - IV-24.

  3. Labropoulos N, Jen J, Jen H, Gasparis AP, Tassiopoulos AK. Recurrent deep vein thrombosis long-term incidence and natural history. Ann Surg 2010; 251: 749-53

  4. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ, et al. American college of chest physicians. Antithrombotic therapy for venous thromboembolic disease: American college of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133: 454S-545S.

  5. Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento F, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologia 2007; 92: 199-205.

  6. Eischer L, Eichinger S, Kyrle PA. Age at first venous thromboembolism and risk of recurrence: a prospective cohort study. Medicine 2009; 88: 366-70.

  7. Ribeiro DD, Lijfering WM, Berrato SM, Rosendaal FR, Rezende SM. Epidemiology of recurrent venous thrombosis. Braz J Med Biol Res 2012; 45: 1-7.

  8. Prandoni P, Lensing AW, Prins MH, Bernardi E, Marchiori M, Bagatella P, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002; 137: 955-60.

  9. Faber DR, DE Groot PG, Visseren FL. Role of adipose tissue in hemostasis, coagulation and fibrinólisis. Obes Rev 2009; 10: 554-63.

  10. Ramualdi E, Squizzato A, Ageno W. Abdominal obesity and the risk of recurrent deep vein thrombosis. Thrombosis Research 2007; 119: 687-90.

  11. Van den Belt AGM, Sanson BJ, Simioni P, Prandoni P, Buller A, Girolami A, et al. Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med 1997; 157: 2227-32.

  12. Santamaria MG, Agnelli G, Taliani MR, Pradoni P, Moia M, Bazzan M, et al. Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment. Thrombosis Research 2005; 16: 301-6.

  13. Prandoni P, Lensing AWA, Bernardi E, Villalta S, Bagatella P, Girolami A, et al. The diagnostic value of compression ultrasonography in patients with suspected recurrent deep vein thrombosis. Thromb Haemost 2002; 88: 402-6.

  14. Linkins L, Strertton R, Pobyn L, Keaton C. Interobserver agreement of ultrasound measurments of residual vein diameter thrombus echogenicity and Doppler venous flow in patients with previous venous thrombosis. Thrombosis Research 2006; 117: 241-7.

  15. Douketis JD, Crowther MA, Foster GA, Ginsberg JS. Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis? Am J Med 2001; 110: 515.

  16. Prandoni P, Lensing AWA, Cogo R, et al. The long-term clinical course of acute deep vein thrombosis. Ann Intern Med 1996; 155: 1-7.

  17. Prandoni P, Villalta S, Bagatella P, Rossi L, Marchiori A, Piccioli A, et al. Clinical course of deep- vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica 1997; 82: 423-8.

  18. Baglin T, Douketis J, Tosetto A, Marcucci M, Cushman M, Kyrle P, et al. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. J Thromb Haemost 2010; 8: 2436-42.

  19. McColl MD, Ellison J, Greer IA, Tait RC, Walker ID. Prevalence of the post-thrombotic syndrome in young women with previous venous thrombo-embolism. Br J Haematol 2000; 108: 272-4.

  20. López-Azkarreta I, Reus S, Marco P, Sánchez-Payá J, Murcia J, Manso MI. Estudio prospectivo de los factores de riesgo de desarrollo de síndrome postrombótico tras una trombosis venosa profunda proximal. Med Clin (Barc) 2005; 125(1): 1-4.

  21. Simsek S, van den Berg FG, Nanayakkara PW, Rauwerda JA, Stehouwer CD. Anomaly of the inferior vena cava causing recurrent deep vein thrombosis in a young male. Eur J Internal Med 2004; 15: 251-4.

  22. Linkins LA, Pasquale P, Paterson S, Kearon C. Change in thrombus length on venous ultrasound and recurrent deep vein thrombosis. Arch Intern Med 2004; 164: 1793-6.

  23. Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism the Vienna prediction model. Circulation 2010; 121: 1630-6.

  24. Ridker PM, Goldhaber SZ, Danielson E, et al. for the PREVENT Investigators. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348: 1425-34.

  25. Kearon C, Ginsberg JS, Kovacs MJ, et al. for the Extended Low-Intensity anticoagulation for thrombo-embolism investigators. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349: 631-9.

  26. Agnelli G, Prandoni P, Santamaria MG, et al. The warfarin optimal duration Italian trial investigators. N Engl J Med 2001; 345: 165-9.

  27. EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499.

  28. EINSTEIN-PE Investigators, Büller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287.

  29. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799.

  30. Schulman S, Kearon C, Kakkar AK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368: 709.

  31. Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366: 1959.

  32. Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012; 367: 1979.

  33. Warkentin TE. Aspirin for dual prevention of venous and arterial thrombosis. N Engl J Med 2012; 367: 2039.

  34. Simes J, Becattini C, Agnelli G, et al. Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. Circulation 2014; 130: 1062.

  35. Castellucci LA, Cameron C, Le Gal G, et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ 2013; 347: f5133.

  36. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139: 893.

  37. Bauer KA. Low intensity warfarin: is it clinically useful in venous thromboembolism management? Br J Haematol 2004; 127: 155.

  38. Locadia M, Bossuyt PM, Stalmeier PF, et al. Treatment of venous thromboembolism with vitamin K antagonists: patients’ health state valuations and treatment preferences. Thromb Haemost 2004; 92: 1336.

  39. Aujesky D, Smith KJ, Roberts MS. Oral anticoagulation strategies after a first idiopathic venous thromboembolic event. Am J Med 2005; 118: 625.

  40. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105: 91.

  41. Campbell IA, Bentley DP, Prescott RJ, Routledge PA, Shetty HG, Williamson IJ. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. BMJ 2007; 334: 674.

  42. Prandoni P, Prins MH, Lensing AW, Ghirarduzzi A, Ageno W, Imberti D, et al; AESOPUS Investigators. Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med 2009; 150: 577-85.

  43. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after depp vein thrombosis: incidence and risk factors. Arch Intern Med 2000; 160: 769-74.

  44. Beyth RJ, Cohen AM, Oandefeld CS. Long-term outcomes of deep-vein thrombosis. Arch Intern Med 1995; 155: 1031-7.

  45. Andresen MS, Sandven I, Brunborg C, Njaastad AM, Strekerud F, Abdelnoor M. et al. Mortality and recurrence after treatment of VTE: Long term follow-up of patients with good life expectancy. Thrombosis Research 2011; 127: 540-6.

  46. White RH, Zhou H, Murin S. Death due to recurrent thromboembolism among younger healthier individuals hospitalized for idiopathic pulmonary embolism. Thromb Haemost 2008; 99: 683-90.

  47. Verso M, Agnelli G, Ageno W, Imberti D, Moia M, Palareti G, et al. Long-term death and recurrence in patients with acute venous thromboembolism: The MASTER registry. Thrombosis Research 2012; 130: 369-73.

  48. Wu C, Alotaibi GS, Alsaleh K, Linkins L, McMurtry MS. Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention. Thrombosis Research 2015; 135: 243-8.

  49. Ageno W, Samperiz A, Caballero R, Dentali F, Di Micco P, Prandoni P, et al. Duration of anticoagulation after venous thromboembolism in real world clinical practice. Thrombosis Research 2015; 135: 666-72.

  50. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline. Chest 2016. Doi: 10.1016/j.chest.2015.11.026.




2020     |     www.medigraphic.com